1. |
Travis WD. The 2015 WHO classification of lung tumors. Pathologe, 2014, 35(Suppl 2): 188.
|
2. |
DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin, 2014, 64(4): 252-271.
|
3. |
Li L, Li W, Chen N, et al. FLI1 exonic circular RNAs as a novel oncogenic driver to promote tumor metastasis in small cell lung cancer. Clin Cancer Res, 2019, 25(4): 1302-1317.
|
4. |
Nisman B, Biran H, Ramu N, et al. The diagnostic and prognostic value of ProGRP in lung cancer. Anticancer Res, 2009, 29(11): 4827-4832.
|
5. |
Salgia R, Weaver RW, McCleod M, et al. Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase Ⅱ study. Invest New Drugs, 2017, 35(3): 334-344.
|
6. |
Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell, 2010, 140(6): 883-899.
|
7. |
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science, 2011, 331(6024): 1565-1570.
|
8. |
Wang F, Li P, Li FS. Prognostic role of C-reactive protein to albumin ratio in colorectal cancer: a meta analysis. Medicine, 2019, 98(29): e16064.
|
9. |
Tuomisto AE, Mäkinen MJ, Väyrynen JP. Systemic inflammation in colorectal cancer: underlying factors, effects, and prognostic significance. World J Gastroenterol, 2019, 25(31): 4383-4404.
|
10. |
Li B, Zhou P, Liu YJ, et al. Platelet-to-lymphocyte ratio in advanced cancer: review and meta-analysis. Clin Chim Acta, 2018, 483: 48-56.
|
11. |
Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Appl Eng Agric, 2014, 18(6): 727-734.
|
12. |
Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 2007, 8: 16.
|
13. |
Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions version 5.1. 0 [updated March 2011]. The Cochrane Collaboration, 2011. http://www.cochrane-handbook.org.
|
14. |
Higgins JT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med, 2002, 21(11): 1539-1558.
|
15. |
Hong X, Cui B, Wang M, et al. Systemic immune-inflammation index, based on platelet counts and neutrophil-lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer. Tohoku J Exp Med, 2015, 236(4): 297-304.
|
16. |
Kang MH, Go SI, Song HN, et al. The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer. Br J Cancer, 2014, 111(3): 452-460.
|
17. |
Liu D, Huang Y, Li L, et al. High neutrophil-to-lymphocyte ratios confer poor prognoses in patients with small cell lung cancer. BMC Cancer, 2017, 17(1): 882.
|
18. |
Sakin A, Sahin S, Yasar N, et al. The relation between hemogram parameters and survival in extensive-stage small cell lung cancer. Oncol Res Treat, 2019, 42(10): 506-515.
|
19. |
Suzuki R, Wei X, Allen PK, et al. Prognostic significance of total lymphocyte count, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio in limited-stage small-cell lung cancer. Clin Lung Cancer, 2019, 20(2): 117-123.
|
20. |
Xie D, Marks R, Zhang MR, et al. Nomograms predict overall survival for patients with small-cell lung cancer incorporating pretreatment peripheral blood markers. J Thorac Oncol, 2015, 10(8): 1213-1220.
|
21. |
Zhang Q, Qu Y, Liu H, et al. Initial platelet-to-lymphocyte count as prognostic factor in limited-stage small cell lung cancer. Biomark Med, 2019, 13(4): 249-258.
|
22. |
Wu F, Yang S, Tang X, et al. Prognostic value of baseline hemoglobin-to-red blood cell distribution width ratio in small cell lung cancer: a retrospective analysis. Thorac Cancer, 2020, 11(4): 888-897.
|
23. |
Shen XB, Wang Y, Shan BJ, et al. Prognostic significance of platelet-to-lymphocyte ratio (PLR) and mean platelet volume (MPV) during etoposide-based first-line treatment in small cell lung cancer patients. Cancer Manag Res, 2019, 11: 8965-8975.
|
24. |
王立伟, 王键玮, 贾伟, 等. 血小板与淋巴细胞比值同小细胞肺癌临床预后的相关性分析. 肿瘤代谢与营养电子杂志, 2019, 6(2): 196-199.
|
25. |
Deng M, Ma XE, Liang X, et al. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?. Oncotarget, 2017, 8(23): 37200-37207.
|
26. |
王鑫, 支修益. 中性粒细胞/淋巴细胞比值和血小板/淋巴细胞比值对小细胞肺癌患者预后价值的相关研究. 中国医学前沿杂志(电子版), 2017, 9(5): 106-110.
|
27. |
Lohinai Z, Bonanno L, Aksarin A, et al. Neutrophil-lymphocyte ratio is prognostic in early stage resected small-cell lung cancer. PeerJ, 2019, 7: e7232.
|
28. |
Wang X, Teng F, Kong L, et al. Pretreatment neutrophil-to-lymphocyte ratio as a survival predictor for small-cell lung cancer. Onco Targets Ther, 2016, 9: 5761-5770.
|
29. |
Chen CJ, Yang HT, Cai D, et al. Preoperative peripheral blood neutrophil-to-lymphocyte ratios (NLR) and platelet-to-lymphocyte ratio (PLR) related nomograms predict the survival of patients with limited-stage small-cell lung cancer. Transl Lung Cancer Res, 2021, 10(2): 866-877.
|
30. |
Zhou X, Du Y, Huang Z, et al. Prognostic value of PLR in various cancers: a meta-analysis. PLoS One, 2014, 9(6): e101119.
|
31. |
Templeton AJ, Ace O, McNamara MG, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev, 2014, 23(7): 1204-1212.
|
32. |
Zhang H, Gao L, Zhang B, et al. Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: a systematic review and meta-analysis. Sci Rep, 2016, 6: 22618.
|
33. |
Qiang G, Liang C, Xiao F, et al. Prognostic significance of platelet-to-lymphocyte ratio in non-small-cell lung cancer: a meta-analysis. Onco Targets Ther, 2016, 9: 869-876.
|
34. |
Ding N, Pang Z, Shen H, et al. The prognostic value of PLR in lung cancer, a meta-analysis based on results from a large consecutive cohort. Sci Rep, 2016, 6: 34823.
|
35. |
Wojtukiewicz MZ, Sierko E, Hempel D, et al. Platelets and cancer angiogenesis nexus. Cancer Metastasis Rev, 2017, 36(2): 249-262.
|
36. |
Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, et al. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol, 2012, 23(4): 265-273.
|
37. |
Bremnes RM, Busund LT, Kilvær TL, et al. The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer. J Thorac Oncol, 2016, 11(6): 789-800.
|
38. |
Man YG, Stojadinovic A, Mason J, et al. Tumor-infiltrating immune cells promoting tumor invasion and metastasis: existing theories. J Cancer, 2013, 4(1): 84-95.
|
39. |
Lissoni P, Brivio F, Fumagalli L, et al. Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. Int J Biol Markers, 2004, 19(2): 135-140.
|
40. |
Kawai O, Ishii G, Kubota K, et al. Predominant infiltration of macrophages and CD8+ T Cells in cancer nests is a significant predictor of survival in stage Ⅳ nonsmall cell lung cancer. Cancer, 2008, 113(6): 1387-1395.
|